Barclays analyst J. David Anderson raised the firm’s price target on Aspen Aerogels (ASPN) to $4 from $3 and keeps an Underweight rating on the shares. The company reported “modestly disappointing” Q1 results with EBITDA below consensus, the analyst tells investors in a research note. The firm says Aspen sounded confident on its European thermal barrier momentum.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASPN: